Hype or hope? The developing evidence base for psychedelic treatment of addiction disorders.
The British Journal of Psychiatry March 21, 2025 DOI: 10.1192/bjp.2025.19 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Editorial Randomized Peer reviewed |
|---|---|
| Topics | Addiction |
| Keywords | Psychedelic Addictions Clinical trials Evidence-based mental health Substance use disorders |
| Citations | 1 |
| Key points | Reviews evidence from randomized trials on psychedelic compounds for addiction disorders and discusses future research directions. |
Abstract
There has been substantial recent renewed interest and investment to assess the therapeutic potential of psychedelic compounds in addiction disorders. This editorial discusses the available evidence from randomised trials and future research directions in the field, together with potential implications for patients, professionals and the wider addiction treatment system.
Citations in the library
Cites 7
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder JAMA Psychiatry August 24, 2022
- Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials Journal of Psychopharmacology March 8, 2012
- Residential Psychedelic (LSD) Therapy for the Narcotic Addict Archives of General Psychiatry June 1, 1973
- Ascending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients. Clinical Pharmacology in Drug Development November 1, 2016
- Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges. CNS Drugs October 1, 2024
and 2 more in the library